TLC-2716

TLC-2716 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Jan 16, 2026: “An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial”.

Intervention

1 paper studies it4 findingsUpdated

See all 1 papers on TLC-2716

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country; 1 trial, none about aging.

“resulted in placebo-adjusted reductions up to 38.5% in plasma TG”
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trialNature medicine2026doi:10.1038/s41591-025-04169-6

None of its findings points the other way.

Cells and humans: a single group. Worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • 1 trial, none about aging
  • Funders: École Polytechnique Fédérale de Lausanne and 6 more
  • 4 of 4 findings with company ties
  • 1 of 1 trial sponsored by its developers
  • Human trial1

Studies in people

1 study gave TLC-2716 to people and measured what changed.

What changedDesignPeopleSource

down: Decreases lipid accumulation

down: Decreases triglycerideplacebo-adjusted reductions up to 38.5%

down: Decreases remnant cholesterolplacebo-adjusted reductions up to 61%

Randomized trial14-daySteatohepatitis modelNature medicine, Jan 16, 2026

What did studies of TLC-2716 find?

4

Studies of TLC-2716 measured 4 outcomes, among them remnant cholesterol, triglyceride and inflammation.

Remnant cholesterol

downin humans1

1 study
  1. TLC-2716 decreases remnant cholesterol in humans (placebo-adjusted reductions up to 61%).

    “and 61% in postprandial remnant cholesterol”

    Human trial14-day

    An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

    Nature medicine

More on Remnant cholesterol

Triglyceride

downin humans1

1 study
  1. TLC-2716 decreases triglyceride in humans (placebo-adjusted reductions up to 38.5%).

    “resulted in placebo-adjusted reductions up to 38.5% in plasma TG”

    Human trial14-day

    An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

    Nature medicine

More on Triglyceride

Inflammation

downin human cells1

1 study
  1. TLC-2716 decreases inflammation in human cells (steatohepatitis model).

    “TLC-2716 reduced lipid accumulation and suppressed inflammation and fibrotic gene expression.”

    Cellssteatohepatitis modelliver

    An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

    Nature medicine

More on Inflammation

Lipid accumulation

downin human cells1

1 study
  1. TLC-2716 decreases lipid accumulation in human cells (steatohepatitis model).

    “TLC-2716 reduced lipid accumulation and suppressed inflammation and fibrotic gene expression.”

    Cellssteatohepatitis modelliver

    An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

    Nature medicine

Who is developing TLC-2716?

1 company: OrsoBio.

Companies

Trial sponsors

  • OrsoBio

    Company1 trialPhase 1100 people

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months